BiotechTube

Herombopag tablets + Herombopag placebo tablets

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

Conditions

Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

Trial Timeline

Jul 31, 2024 → Dec 1, 2025

NCT ID
NCT06507436

About Herombopag tablets + Herombopag placebo tablets

Herombopag tablets + Herombopag placebo tablets is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06507436. Target conditions include Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery.

What happened to similar drugs?

2 of 20 similar drugs in Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery were approved

Approved (2) Terminated (2) Active (16)
✅Standard heparin (UFH) versus certoparin (LMWH)NovartisApproved
✅romiplostimAmgenApproved
🔄avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
🔄avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
🔄Avatrombopag + Placebo + Standard of careEisaiPhase 3
🔄Romiplostim + PlaceboKyowa KirinPhase 3
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06507436Phase 3Recruiting

Competing Products

20 competing products in Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + PlaceboEli LillyPhase 1/2
39
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
17
Placebo + LusutrombopagShionogiPhase 2
27
LusutrombopagShionogiPhase 2
27
Avatrombopag + Avatrombopag + PlaceboEisaiPhase 2
35
avatrombopagEisaiPhase 1
29
E5501 + Drug: E5501EisaiPhase 1
29
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
40
avatrombopag + PlaceboEisaiPhase 2
35
Avatrombopag + Placebo + Pegylated interferon (PEG-IFN) + Telaprevir + RibavirinEisaiPhase 2
35
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
40
Avatrombopag + Placebo + Standard of careEisaiPhase 3
40
RomiplostimKyowa KirinPhase 1/2
32
Romiplostim + PlaceboKyowa KirinPhase 3
40
Romiplostim (AMG-531)Kyowa KirinPhase 2
35
Romiplostim and danazolKyowa KirinPhase 2
31
ONO-7746Ono PharmaceuticalPhase 1
21
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
29
Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
47
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 2
42